机构：[1]Chinese Acad Med Sci, Canc Hosp, Dept Abdominal Surg Oncol, Beijing, Peoples R China;[2]Peking Union Med Coll, Beijing, Peoples R China;[3]Peking Union Med Coll, Acad Med Sci, Beijing, Peoples R China;[4]Capital Med Univ, Beijing Tiantan Hosp, Dept Gastroenterol, Beijing, Peoples R China;诊疗科室消化内科首都医科大学附属天坛医院[5]Chinese Acad Med Sci, Canc Hosp, Dept Internal Med, Beijing, Peoples R China;[6]Chinese Acad Med Sci, Peking Union Med Coll, Inst Basic Med Sci, State Key Lab Med Mol Biol, Beijing, Peoples R China;[7]Chinese Acad Med Sci, Canc Hosp, Lab Cell & Mol Biol, Beijing, Peoples R China
Background: Treatment for midgut neuroendocrine tumor patients with unresectable liver metastasis has long been a controversial issue. This system review aims to summarize existing evidence concerning the value of primary tumor resection in this group of patients. Results: 8 cohort studies were identified for qualitative analysis. None of them strictly met with the inclusion criteria and meta-analysis was impossible. There was a tendency towards better overall survival for the primary tumor resected group in all 8 studies, in which 6 demonstrated significant difference. Progression free survival to liver disease was prolonged and less patients died of liver failure in the resected group. Methods: MEDLINE, EMBASE and CENTRAL were searched until 2016/7/4 for relevant studies, with primary outcome being overall survival, and secondary outcome being progression free survival, cause of death and symptom relief. Conclusions: Current evidence supports resection of primary tumor for midgut neuroendocrine tumor patients with liver metastases, but randomized controlled trials are required to reach a final conclusion.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81201967, 81672461, 81350007]; National High-tech R&D (863) Program of ChinaNational High Technology Research and Development Program of China [2015AA020408]; capital health research and development of special [2014-1-4022]; National Program on Key Basic Research Project of China (973 Program)National Basic Research Program of China [2014CBA02000]
第一作者机构：[1]Chinese Acad Med Sci, Canc Hosp, Dept Abdominal Surg Oncol, Beijing, Peoples R China;[2]Peking Union Med Coll, Beijing, Peoples R China;[3]Peking Union Med Coll, Acad Med Sci, Beijing, Peoples R China;
通讯作者：
通讯机构：[1]Chinese Acad Med Sci, Canc Hosp, Dept Abdominal Surg Oncol, Beijing, Peoples R China;[2]Peking Union Med Coll, Beijing, Peoples R China;
推荐引用方式(GB/T 7714)：
Guo Jingfei,Zhang Qian,Bi Xinyu,et al.Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastases[J].ONCOTARGET.2017,8(10):17396-17405.doi:10.18632/oncotarget.14156.
APA：
Guo, Jingfei,Zhang, Qian,Bi, Xinyu,Zhou, Jianguo,Li, Zhiyu...&Zhao, Hong.(2017).Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastases.ONCOTARGET,8,(10)
MLA：
Guo, Jingfei,et al."Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastases".ONCOTARGET 8..10(2017):17396-17405
医学